TTTY7A: A Protein Implicated in Neurodegenerative Diseases (G246122)

Target Name: TTTY7

NCBI ID: G246122

TTTY7

TTTY7A: A Protein Implicated in Neurodegenerative Diseases

TTTY7 (TTTY7A) is a protein that is expressed in the brain and is known for its role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is composed of 700 amino acids and has a molecular weight of 19.9 kDa. It is located in the endoplasmic reticulum and is involved in the regulation of a variety of cellular processes, including cell signaling, neurotransmitter release, and synaptic plasticity.

TTTY7A is a member of the tyrosine kinase family and is involved in the signaling pathway known as the TKI-SP signaling pathway. This pathway is important for the regulation of neurotransmitter release and for the development of synaptic plasticity, which is the ability of the brain to change and adapt over time.

Research has shown that TTTY7A is involved in the development of neurodegenerative diseases, including Alzheimer's disease. Studies have shown that individuals with Alzheimer's disease have lower levels of TTTY7A in their brains than healthy individuals. Additionally, individuals with certain genetic mutations, such as those in the APTN3 gene, have been shown to have increased levels of TTTY7A in their brains and to be at increased risk for developing neurodegenerative diseases.

TTTY7A is also a potential drug target for the treatment of neurodegenerative diseases. Studies have shown that blocking the activity of TTTY7A using small molecules can improve the cognitive function of individuals with Alzheimer's disease. Additionally, administering small molecules that inhibit the activity of TTTY7A have been shown to reduce the formation of beta-amyloid plaques, a hallmark of Alzheimer's disease, in both animal models and human clinical trials.

TTTY7A is also a potential biomarker for the diagnosis and monitoring of neurodegenerative diseases. Studies have shown that the levels of TTTY7A in brain tissue can be used as a reliable indicator of the severity of neurodegenerative diseases, such as Alzheimer's disease. Additionally, the levels of TTTY7A in brain tissue have been shown to be affected by a variety of factors, including disease severity, treatment, and neuroprotective agents, which could be used to monitor the effectiveness of different treatments for neurodegenerative diseases.

In conclusion, TTTY7A is a protein that is involved in the regulation of various cellular processes in the brain and is potentially involved in the development and progression of neurodegenerative diseases. The levels of TTTY7A in brain tissue can be used as a potential biomarker for the diagnosis and monitoring of these diseases. Additionally, blocking the activity of TTTY7A using small molecules has been shown to improve cognitive function and reduce the formation of beta-amyloid plaques in animal models and human clinical trials, making it a potential drug target for the treatment of neurodegenerative diseases. Further research is needed to fully understand the role of TTTY7A in neurodegenerative diseases and to develop effective treatments.

Protein Name: Testis-specific Transcript, Y-linked 7

The "TTTY7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TTTY7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets